The incidence of cancer is increasing; however, mortality rates have decreased in the past 30 years, largely because of increased awareness and early detection methods. The majority of cancer cases are treated as serious conditions, but not all are considered urgent. Some cases, known as oncologic emergencies, are identified as critical. This article discusses the diagnosis and treatment of common and potentially life-threatening oncologic emergencies such as metabolic, hematologic, and structural emergencies, as well as the role of the radiologic technologist and cancer care team.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges.
Expert Rev Anticancer Ther
March 2025
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Introduction: Prostate cancer represents a significant oncological challenge, with its natural history predominantly driven by androgen receptor (AR) signaling. The pivotal role of this pathway underscores the rationale for targeting AR activity in therapeutic strategies. However, the development of resistance mechanisms has highlighted the need for advanced therapies to address the complexity of the castration-resistant status.
View Article and Find Full Text PDFCervical cancer in pregnancy.
Semin Perinatol
March 2025
Lab of Gynecological Oncology, Department of Oncology, KU Leuven, Leuven, Belgium; Department of Obstetrics and Gynecology, UZ Leuven, Leuven, Belgium; Department of Gynecologic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address:
Cervical cancer is one of the most common and challenging malignancies diagnosed during pregnancy, requiring a complex balance between effective oncological management and pregnancy preservation. This narrative review synthesizes current evidence and clinical experience regarding the management of cervical cancer in pregnant patients. While treatment should generally follow standard protocols for nonpregnant patients, emerging data suggest that pregnancy can often be safely maintained without compromising oncological outcomes.
View Article and Find Full Text PDFInitial outcomes of a single-institution hepatic artery infusion pump program for colorectal liver metastases and intrahepatic cholangiocarcinoma: Safety, feasibility, and circulating tumor DNA tracking.
Surgery
March 2025
Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH.
Background: Hepatic artery infusion with floxuridine is a treatment option for patients with colorectal liver metastases or intrahepatic cholangiocarcinoma. Outcomes from newer centers are understudied. Predictive markers are needed, and quantitative circulating tumor DNA is an emerging candidate method for predicting response in patients receiving hepatic artery infusion.
View Article and Find Full Text PDFTransformative Effects of Fluorescence Imaging Technologies on Current Vascular Surgical Practices: An Updated Review.
SLAS Technol
March 2025
Department of Vascular Surgery, Yantai Mountain Hospital, Yantai 264001, China. Electronic address:
Fluorescence imaging technologies have revolutionized vascular surgery by enabling real-time visualization of vascular anatomy, blood circulation, and tissue perfusion, thus improving intraoperative decision-making. This review provides a comprehensive analysis of key fluorescence modalities, including Fluorescence-Guided Surgery (FGS), Near-Infrared (NIR) fluorescence imaging, and Indocyanine Green (ICG) angiography, highlighting their roles in optimizing tissue perfusion assessment, vessel patency evaluation, and identifying anatomical variations. Unlike existing literature, this review addresses critical gaps in current practices by comparing these technologies and exploring their applications across a range of vascular procedures such as peripheral vascular surgery, coronary artery bypass grafting, and oncological operations.
View Article and Find Full Text PDFHuman CSPG4-targeting CAR-macrophages inhibit melanoma growth.
Oncogene
March 2025
Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT, 84112, USA.
Approximately half of melanoma patients relapse or fail to respond to current standards of care, highlighting the need for new treatment options. Engineering T-cells with chimeric antigen receptors (CARs) has revolutionized the treatment of hematological malignancies but has been clinically less effective in solid tumors. We therefore sought to engineer alternative immune cell types to inhibit melanoma progression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!